Curium US LLC

Curium US LLC is the American subsidiary of Curium Pharma, a global leader in radiopharmaceuticals. Founded in 2017 through the union of IBA Molecular and Mallinckrodt Nuclear Medicine LLC, Curium Pharma is a privately held company backed by CapVest. While Curium Pharma's international headquarters are in Paris, France, and its global headquarters are in Boston, Massachusetts, Curium US LLC maintains addresses in Maryland Heights and St. Louis, Missouri. The parent company employs over 5,000 individuals worldwide, with estimated annual revenues ranging from $459.3 million to $725 million, and was valued at approximately $7 billion in a November 2025 recapitalization.

Curium focuses on the development, manufacturing, and supply of radiopharmaceutical products for nuclear medicine. Their extensive portfolio includes SPECT, PET, and therapeutic radiopharmaceuticals, such as generators, cold kits, hot products, and auxiliary products. These are used in the diagnosis and treatment of various diseases, particularly cancer, and conditions affecting organs like the thyroid, lungs, liver, bones, brain, heart, glands, kidneys, and joints. The company operates a significant manufacturing and distribution network across Europe and the United States.

Curium US LLC's patent litigation posture is currently characterized by a single case as a plaintiff and zero as a defendant, indicating it is not an NPE but an operating company actively engaging in patent challenges. This sole tracked case is an Inter Partes Review (IPR) filed at the Patent Trial and Appeal Board (PTAB). In this proceeding, Curium US LLC is challenging the validity of a patent, a common strategy for operating companies seeking to clear obstacles related to their product development or market entry.

The notable case, Curium US LLC v. Universität Heidelberg, IPR2025-01582, involves a challenge to Patent No. 10,980,901 B2, which pertains to methods for treating cancers characterized by the overexpression of prostate-specific membrane antigen (PSMA) using radiopharmaceuticals. This aligns directly with Curium Pharma's strategic focus on oncology and the expansion of its theranostics pipeline, including radioligand therapies for prostate cancer. Initially, Curium US LLC faced scrutiny regarding its disclosure of real parties-in-interest in the IPR, leading to an updated filing that included its parent entities and a new filing date for the petition.